Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
about
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
P2860
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
@ast
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
@en
type
label
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
@ast
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
@en
prefLabel
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
@ast
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
@en
P356
P1476
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia
@en
P2093
John M Goldman
Tariq I Mughal
P356
10.3816/CLM.2007.S.006
P478
P577
2007-03-01T00:00:00Z